If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
146.00    0.00 (0.00%)
Bid:
145.00
Ask:
147.00
Spread: 2.00 (1.379%)
Market Cap: £123.56m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Senior Management Appointments

11 Jul 2024 07:00

RNS Number : 9478V
Diaceutics PLC
11 July 2024
 

Diaceutics Makes Four Senior Management Appointments

VP Chief of Staff, VP of Human Resources, VP of Engagement Solutions and VP of Real-World Data

New roles will further strengthen management team and drive continued innovation, performance & growth at Diaceutics

 

Belfast and London, 11 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce four appointments to its executive team. These appointments are part of Diaceutics' commitment to strong governance and ensuring it has the structure in place to capitalise upon the growth in its market. The new Vice Presidents - Madeline Brown, Norma Thompson, Gosia Leitch, and Scott Phillips - bring a wealth of experience and expertise to their respective roles and will add significant strength to Diaceutics' leadership team and as it drives continued innovation, performance and growth.

Diaceutics CEO Ryan Keeling said, "Madeline, Norma, Gosia, and Scott are dynamic leaders whose extensive experience, vision and innovative approaches will be crucial in shaping Diaceutics' future performance and growth. As we continue to expand, their perspectives will be essential to helping us reach our full potential."

Madeline Brown, VP, Chief of Staff

Madeline Brown has been with Diaceutics since 2007, holding significant roles in finance and strategic project management. She will now lead the Chief Executive's Office, focusing on driving efficiencies and scalability.

Norma Thompson, VP of Human Resources

Norma Thompson joined Diaceutics in 2019 as Global Head of Human Resources. With over 30 years of experience, she brings extensive knowledge in HR management, talent development, and regulatory environments, essential for Diaceutics' global operations.

Gosia Leitch, VP of Engagement Solutions

Gosia Leitch has over 20 years of experience in diagnostics and pharma, including roles at Veracyte, Abbott, Qiagen, Bayer Healthcare and SC Johnson. She will drive engagement strategies connecting diagnostics with the broader healthcare ecosystem.

Scott Phillips, VP of Real-World Data

Scott Phillips brings over 12 years of experience in real-world data, product development, strategy consulting, and business development. Previously at Komodo Health and COTA Healthcare, he will enhance Diaceutics' data strategy and integration of real-world evidence.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Enquiries:

Diaceutics PLC 

Ryan Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison, Nick Harland, Kate Hanshaw 

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon, Kieran Breheny

diaceutics@almastrategic.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGMNRGDGDZM
Date   Source Headline
1st Nov 20227:00 amRNSSub-optimal testing impacts on cancer patients
31st Oct 20222:20 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20225:03 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20227:00 amRNSPurchase of Shares and PDMR Shareholding
27th Sep 20227:00 amRNSHalf-year Report
12th Sep 202212:38 pmRNSPDMR Shareholding/Share Incentive Plan
8th Sep 20227:00 amRNSNotice of Results and Presentations
8th Aug 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
26th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Jul 20225:45 pmRNSPDMR Shareholding/Share Incentive Plan
13th Jun 20227:00 amRNSMulti-year contract with top five global pharma
7th Jun 20227:00 amRNSNew AI and ML Capabilities Enhance DXRX Platform
31st May 202212:12 pmRNSPDMR Shareholding/Share Incentive Plan
27th May 20224:31 pmRNSShare Options and PDMR Shareholdings
26th May 20223:00 pmRNSResult of AGM
11th May 20222:34 pmRNSPDMR Shareholding/Share Incentive Plan
9th May 20224:37 pmRNSExercise of Warrant & Total Voting Rights
5th May 20227:00 amRNSContract Win
29th Apr 20225:22 pmRNSPDMR Shareholding/Share Incentive Plan
28th Apr 20222:09 pmRNSNotice of AGM and Posting of Annual Report
7th Apr 20227:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
6th Apr 20221:13 pmRNSPDMR Shareholding/Share Incentive Plan
5th Apr 20223:49 pmRNSConversion of Convertible Loan Notes & TVR
1st Apr 20227:00 amRNSIssue of Share Options / PDMR Shareholdings
31st Mar 20225:38 pmRNSPDMR Shareholding/Share Incentive Plan
22nd Mar 20222:43 pmRNSFinal Results
22nd Mar 20227:00 amRNSNotice of 2021 Full Year Results
18th Mar 20222:09 pmRNSConfirmation of Directorate Change
16th Mar 20225:49 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSApproval by CMS for enhanced data access
2nd Mar 20225:37 pmRNSPDMR Shareholding/Share Incentive Plan
21st Feb 20227:00 amRNSInvestor Presentation
14th Feb 20226:26 pmRNSPDMR Shareholding/Share Incentive Plan
14th Feb 20227:00 amRNSContract with leading life sciences company
4th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Jan 20227:01 amRNSDirectorate Change
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins
1st Dec 20215:22 pmRNSPDMR Shareholding/Share Incentive Plan
9th Nov 20214:57 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20211:19 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 202112:32 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSPurchase/Transfer of Shares and PDMR Shareholdings
21st Sep 20217:00 amRNSNominated as finalists for Health Tech Awards 2021
14th Sep 20217:00 amRNSHalf-year Report
13th Sep 20217:00 amRNSDXRX Platform Contract Win
8th Sep 20217:00 amRNSTwo new experts join the Diaceutics Advisory Panel
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.